Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Imatinib in Adult Patients With Metastatic Ocular Melanoma (O-Mel-Inib)

This study has been terminated.
(Study stopped at the end of the first step)
National Cancer Institute, France
Information provided by (Responsible Party):
Centre Oscar Lambret Identifier:
First received: January 9, 2007
Last updated: January 5, 2016
Last verified: January 2016
The scope of the trial is to determinate the anti-tumoral activity of imatinib in metastatic ocular melanoma patients.

Condition Intervention Phase
Drug: Imatinib
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase II Multicentric Trial to Assess Efficacy and Toxicity of Imatinib in Adult Patients With Metastatic Ocular Melanoma

Resource links provided by NLM:

Further study details as provided by Centre Oscar Lambret:

Primary Outcome Measures:
  • Progression-free rate at 3 months

Secondary Outcome Measures:
  • Progression-free rate at 6 and 12 months
  • Response rate according to RECIST criteria
  • Toxicity
  • Global survival,Progression-free survival
  • Predictive genomic factors of response

Enrollment: 13
Study Start Date: December 2005
Study Completion Date: March 2007
Primary Completion Date: March 2007 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Imatinib
    800 mg/day until disease progression or toxicity
Detailed Description:
Further study details as provided by Centre Oscar Lambret

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Metastatic ocular melanoma
  • Age > or = 18 years old
  • Measurable metastases > or = 10 mm according to RECIST criteria
  • PS-WHO < or = 1 or IK > 70 percent
  • Normal hepatic function
  • PNN > 1500/mm3, platelets > or = 100 000/mm3
  • Contraception
  • Informed consent signed

Exclusion Criteria:

  • Patient with two prior lines of systemic treatment (chemotherapy, immunotherapy or association)
  • Other evolutive neoplasic disease
  • Severe hepatic insufficiency
  • Severe renal insufficiency
  • Somatic or psychiatric co-morbidity incompatible with the protocol
  • Leptomeningeal or cerebral metastatic dissemination
  • Pregnant or lactating woman
  • Other antitumoral treatment
  • Patient participating to another clinical trial with an experimental drug
  • Known hypersensitivity to Imatinib or one of its excipients
  • Resecable single metastasis
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00421317

Centre Francois Baclesse
Caen, France, 14076
Centre Jean Perrin
Clermont-Ferrand, France, 63011
Centre Georges-Francois Leclerc
Dijon, France, 21079
Centre Oscar Lambret
Lille, France, 59020
Centre Hospitalier Regional Universitaire
Lille, France, 59035
Centre Leon Berard
Lyon, France, 69373
Centre Val d'Aurelle Paul Lamarque
Montpellier, France, 34298
Institut Curie
Paris, France, 75248
Centre Paul Strauss
Strasbourg, France, 67065
Hopital Universitaire de Hautepierre
Strasbourg, France, 67098
Institut Claudius Regaud
Toulouse, France, 31052
Centre Gustave Roussy
Villejuif, France, 94805
Sponsors and Collaborators
Centre Oscar Lambret
National Cancer Institute, France
Principal Investigator: PENEL Nicolas, MD Centre Oscar Lambret
  More Information

Responsible Party: Centre Oscar Lambret Identifier: NCT00421317     History of Changes
Other Study ID Numbers: O-Mel-Inib 0508
Study First Received: January 9, 2007
Last Updated: January 5, 2016

Keywords provided by Centre Oscar Lambret:
Ocular, Metastatic melanoma

Additional relevant MeSH terms:
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Nevi and Melanomas
Imatinib Mesylate
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on May 25, 2017